Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5912303 | Multiple Sclerosis and Related Disorders | 2016 | 8 Pages |
Abstract
HERV-W was expressed in demyelinated lesions from MS brains, which were all positive for this endogenous pathogenic protein. Pronounced HERV-W immunoreactivity in active MS lesions was intimately associated with areas of active demyelination throughout the successive stages of lesion evolution in MS brains. Based on its pathogenic potential, this HERV-W (MSRV) endogenous toxin thus appears to be a novel therapeutic target in MS. It also has a unique positioning as an early and lifelong expressed pathogenic agonist, acting upstream the pathways in which dysregulated physiological effectors are usually targeted by present therapeutic strategies for MS.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Jack van Horssen, Susanne van der Pol, Philip Nijland, Sandra Amor, Hervé Perron,